Fmoc-L-Asu(NH-OtBu)-OH

Nombre químico: N-alpha-(9-Fluorenylmethyloxycarbonyl)-L-aminosuberic acid 8-t-butyl amide // Sinónimos: (S)-Fmoc-2-amino-suberic acid-8-t-butyl amide, (S)-Fmoc-Asu(NH-OtBu)-OH, (S)-Fmoc-2-amino-octanedioic acid-8-tert-butyl amide,(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-8-(tert-butoxyamino)-8 -oxooctanoic acid, Fmoc-Asu(NH-OtBu)-OH

Nº Artículo:FAA8295
Nº CAS:2307603-50-3
Fórmula:C₂₇H₃₄N₂O₆
Storage temperature:-20°C
Masa molecular:482,58 g/mol

from 225,00 €

Grouped product items
Cantidad	Unidad de venta	Precio	Unidad de almacenamiento de stock (SKU)	Disponibilidad
	100 mg	225,00 €	FAA8295.0100	<10 días laborables
	250 mg	450,00 €	FAA8295.0250	<10 días laborables
	1 g	1.350,00 €	FAA8295.1000	<10 días laborables
Hoja de seguridad

Skip to the beginning of the images gallery

description

Histone deacetylases (HDACs), pivotal enzymes in the regulation of gene expression, can be efficiently inhibited by substrate peptidomimetic inhibitors (SPIs), as shown by Jamiesen et al. The inhibiting properties of SPIs stem from the presence of non-natural amino acids able to coordinate the HDAC active site zinc(II). Such amino acids with chelating properties can be obtained by the suitable placement of functional groups with donor properties within their side chain, such as amino, carbonyl, oxyamino or hydroxyl groups. The building blocks Fmoc-Asu(NH-OtBu)-OH (FAA8295), Fmoc-Lys(carbamoyl-OtBu)-OH (FAA8350), Fmoc-HomoArg(OtBu,Pbf)-OH (FAA8355) and Fmoc-L-Orn(Ac,OBz)-OH (FAA4220) are compatible with standard Fmoc/tBu SPPS protocols and represent ready to use efficient tools for the fine-tuning of the chelating properties of peptides.

references

Synthesis of HDAC Substrate Peptidomimetic Inhibitors Using Fmoc Amino Acids Incorporating Zinc-Binding Groups; A. Mahindra, C. J. Millard, I. Black, L. J. Archibald, J. W. R. Schwabe and A. G. Jamieson; Org Lett 2019; 21: 3178-3182. https://doi.org/10.1021/acs.orglett.9b00885

Probing the structure-activity relationship of endogenous histone deacetylase complexes with immobilized peptide-inhibitors; J. Sindlinger, J. Bierlmeier, L. C. Geiger, K. Kramer, I. Finkemeier and D. Schwarzer; J Pept Sci 2016; 22: 352-9. https://doi.org/10.1002/psc.2875

Interrogating Substrate Selectivity and Composition of Endogenous Histone Deacetylase Complexes with Chemical Probes; A. Dose, J. Sindlinger, J. Bierlmeier, A. Bakirbas, K. Schulze-Osthoff, S. Einsele-Scholz, M. Hartl, F. Essmann, I. Finkemeier and D. Schwarzer; Angew Chem Int Ed Engl 2016; 55: 1192-5. https://doi.org/10.1002/anie.201508174

Histone deacetylase (HDAC) 1 and 2 complexes regulate both histone acetylation and crotonylation in vivo; R. D. W. Kelly, A. Chandru, P. J. Watson, Y. Song, M. Blades, N. S. Robertson, A. G. Jamieson, J. W. R. Schwabe and S. M. Cowley; Scientific reports 2018; 8: 14690. https://doi.org/10.1038/s41598-018-32927-9

HDAC inhibitors: a 2013-2017 patent survey; M. Faria Freitas, M. Cuendet and P. Bertrand; Expert Opin Ther Pat 2018; 28: 1-17. https://doi.org/10.1080/13543776.2018.1459568

Fmoc protected (2s)-2-amino-8-[(1,1-dimethylethoxy)amino]-8-oxo-octanoic acid, (s)-2-amino-8-oxononanoic acid and (s)-2-amino-8-oxodecanoic acid for peptide synthesis; A. Jamieson, A. Mahindra, I. Black; 2019; WO2019219938A1.

* Disclaimer

Prices are excl. tax, excl. shipping.

We refer to our general terms and conditions.
All information contained in our webshop is compiled to the best of our knowledge.
Prices and product availability are subject to change and require reconfirmation. Please contact us for further information.